272 related articles for article (PubMed ID: 24742411)
1. Management of hepatocellular carcinoma -- experience of a single center.
Iliescu L; Mindrut E; Grasu M; Orban C; Tanase A; Toma L
Chirurgia (Bucur); 2014; 109(2):204-7. PubMed ID: 24742411
[TBL] [Abstract][Full Text] [Related]
2. Multimodality treatment involving radiotherapy for advanced liver-confined hepatocellular carcinoma.
Yoon HI; Seong J
Oncology; 2014; 87 Suppl 1():90-8. PubMed ID: 25427739
[TBL] [Abstract][Full Text] [Related]
3. Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib.
Nakazawa T; Hidaka H; Takada J; Okuwaki Y; Tanaka Y; Watanabe M; Shibuya A; Minamino T; Kokubu S; Koizumi W
Eur J Gastroenterol Hepatol; 2013 Jun; 25(6):683-9. PubMed ID: 23395995
[TBL] [Abstract][Full Text] [Related]
4. Hepatocellular carcinoma: options for diagnosing and managing a deadly disease.
Murali AR; Romero-Marrero C; Aucejo F; Menon KV
Cleve Clin J Med; 2013 Oct; 80(10):645-53. PubMed ID: 24085810
[TBL] [Abstract][Full Text] [Related]
5. The Prognostic Value of Alpha-Fetoprotein Response for Advanced-Stage Hepatocellular Carcinoma Treated with Sorafenib Combined with Transarterial Chemoembolization.
Liu L; Zhao Y; Jia J; Chen H; Bai W; Yang M; Yin Z; He C; Zhang L; Guo W; Niu J; Yuan J; Cai H; Xia J; Fan D; Han G
Sci Rep; 2016 Feb; 6():19851. PubMed ID: 26831408
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization.
Ogasawara S; Chiba T; Ooka Y; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Kanai F; Yoshikawa M; Yokosuka O
Oncology; 2014; 87(6):330-41. PubMed ID: 25227534
[TBL] [Abstract][Full Text] [Related]
7. Surgical resection versus transarterial chemoembolization for BCLC stage C hepatocellular carcinoma.
Liu PH; Hsia CY; Lee YH; Hsu CY; Huang YH; Su CW; Lee RC; Lin HC; Huo TI
J Surg Oncol; 2015 Mar; 111(4):404-9. PubMed ID: 25643842
[TBL] [Abstract][Full Text] [Related]
8. Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus-endemic area.
Park KW; Park JW; Choi JI; Kim TH; Kim SH; Park HS; Lee WJ; Park SJ; Hong EK; Kim CM
J Gastroenterol Hepatol; 2008 Mar; 23(3):467-73. PubMed ID: 17764529
[TBL] [Abstract][Full Text] [Related]
9. Determinants of survival following hepatocellular carcinoma in Egyptian patients with untreated chronic HCV infection in the pre-DAA era.
Waziry R; Gomaa A; Waked I; Dore GJ
Arab J Gastroenterol; 2018 Mar; 19(1):26-32. PubMed ID: 29506913
[TBL] [Abstract][Full Text] [Related]
10. Intermediate hepatocellular carcinoma: current treatments and future perspectives.
Dufour JF; Bargellini I; De Maria N; De Simone P; Goulis I; Marinho RT
Ann Oncol; 2013 Apr; 24 Suppl 2():ii24-9. PubMed ID: 23715940
[TBL] [Abstract][Full Text] [Related]
11. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis.
Gramenzi A; Golfieri R; Mosconi C; Cappelli A; Granito A; Cucchetti A; Marinelli S; Pettinato C; Erroi V; Fiumana S; Bolondi L; Bernardi M; Trevisani F;
Liver Int; 2015 Mar; 35(3):1036-47. PubMed ID: 24750853
[TBL] [Abstract][Full Text] [Related]
12. Nationwide study of 4741 patients with non-B non-C hepatocellular carcinoma with special reference to the therapeutic impact.
Utsunomiya T; Shimada M; Kudo M; Ichida T; Matsui O; Izumi N; Matsuyama Y; Sakamoto M; Nakashima O; Ku Y; Kokudo N; Makuuchi M;
Ann Surg; 2014 Feb; 259(2):336-45. PubMed ID: 23673768
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions.
Bolondi L; Burroughs A; Dufour JF; Galle PR; Mazzaferro V; Piscaglia F; Raoul JL; Sangro B
Semin Liver Dis; 2012 Nov; 32(4):348-59. PubMed ID: 23397536
[TBL] [Abstract][Full Text] [Related]
14. Addition of local hepatic therapy to sorafenib in patients with advanced hepatocellular carcinoma (stage BCLC C).
Schmidt L; op den Winkel M; Fischer K; Straub G; Rauch B; Paprottka PM; Göke B; Kolligs FT
Digestion; 2014; 90(4):219-28. PubMed ID: 25502689
[TBL] [Abstract][Full Text] [Related]
15. Surveillance program for early detection of hepatocellular carcinoma in Japan: results of specialized department of liver disease.
Ando E; Kuromatsu R; Tanaka M; Takada A; Fukushima N; Sumie S; Nagaoka S; Akiyoshi J; Inoue K; Torimura T; Kumashiro R; Ueno T; Sata M
J Clin Gastroenterol; 2006; 40(10):942-8. PubMed ID: 17063116
[TBL] [Abstract][Full Text] [Related]
16. Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma.
Gish RG; Finn RS; Marrero JA
Clin Adv Hematol Oncol; 2013 Apr; 11 Suppl 5():1-22; quiz 2 p following p22. PubMed ID: 23881427
[TBL] [Abstract][Full Text] [Related]
17. Optimal treatment increased survival of hepatocellular carcinoma patients detected with community-based screening.
Tseng PL; Wang JH; Tung HD; Hung CH; Kee KM; Chen CH; Chang KC; Lee CM; Changchien CS; Chen PF; Tsai LS; Lu SN
J Gastroenterol Hepatol; 2010 Aug; 25(8):1426-34. PubMed ID: 20659234
[TBL] [Abstract][Full Text] [Related]
18. The 2008 Okuda lecture: Management of hepatocellular carcinoma: from surveillance to molecular targeted therapy.
Kudo M
J Gastroenterol Hepatol; 2010 Mar; 25(3):439-52. PubMed ID: 20370723
[TBL] [Abstract][Full Text] [Related]
19. External validation of a simplified BCLC staging system for early hepatocellular carcinoma.
Santambrogio R; Salceda J; Costa M; Kluger MD; Barabino M; Laurent A; Opocher E; Azoulay D; Cherqui D
Eur J Surg Oncol; 2013 Aug; 39(8):850-7. PubMed ID: 23726257
[TBL] [Abstract][Full Text] [Related]
20. Is it time to adopt external beam radiotherapy in the NCCN guidelines as a therapeutic strategy for intermediate/advanced hepatocellular carcinoma?
Jiang W; Zeng ZC
Oncology; 2013; 84 Suppl 1():69-74. PubMed ID: 23428862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
